Sichuan Province removed 346 kinds of drugs from the list of Medicare drugs

The news that 346 products were moved out of Sichuan Medical Insurance warned the medical representatives behind them: it's time to move and make plans Recently, Sichuan Medical Security Bureau issued a document Since January 1, 2020, the basic medical insurance, work-related injury insurance and maternity insurance of Sichuan Province have fully implemented the national drug catalog, and the generic name, drug classification, dosage form and limited payment scope of drugs have been implemented in accordance with the national regulations The notice explains the local supplementary drugs: if the provincial supplementary drugs have been included in the catalogue of drugs for national basic medical insurance, industrial injury insurance and maternity insurance (hereinafter referred to as "the National Drug Catalogue"), they shall be implemented in accordance with the national regulations; if they have not been included in the national drug catalogue, they shall be implemented temporarily in accordance with the original regulations and gradually digested within 3 years; the deleted varieties in the National Drug Catalogue No more Sichuan Medical Insurance Bureau also attached the list of deleted Western medicines and the list of deleted Chinese patent medicines in the national drug catalog That is to say, 275 Western medicines and 71 Chinese patent medicines have been completely removed from the medical insurance catalogue of Sichuan Province Sichuan is not the first, after Anhui and Hunan provinces have moved On December 13, Hunan Province issued a document clearly stipulating that all localities shall not adjust or separately formulate the medical insurance catalogue in any name, and shall not adjust the proportion of self payment and limit the scope of use without authorization In addition, the notice emphasizes that the drugs supplemented by the original province will be digested year by year, the first batch of national key monitoring catalog varieties will be removed preferentially, and the original catalog varieties of the province that have entered the national drug catalog will be transferred out, and then they will be classified as "drugs within the digestion period" These varieties will be digested year by year within three years according to the national regulations, and the scope of medical insurance will be cleared up, with a total of 404 drugs in the transfer out range Among them, 212 are western medicine and 192 are Chinese patent medicine In the middle of December, there was also a document about non-state drug catalogue varieties (Chinese patent medicine part) in 2017 drug catalogue of Shandong Province, involving 125 varieties The 125 Chinese patent medicines were also moved out of the medical insurance catalogue of Shandong Province Previously, relevant documents stipulated that national class a drugs could not be adjusted, and provinces (regions, cities) could issue local basic medical insurance, work injury insurance and maternity insurance drug catalogue The adjusted quantity (including transfer in, transfer out and restricted payment scope) shall not exceed 15% of the national class B drug quantity (i.e 291 kinds) This gives many products the opportunity to save the country through the local health insurance supplement curve According to the 2017 supplementary data of provinces and cities, Hebei Province has the most supplementary varieties, reaching 635 Jiangxi Province has the largest number of Western medicine supplements, with 451 varieties; Beijing has the largest number of Chinese medicine supplements, with a total of 255 Jia Xiaoqing, the purchasing manager of the retail department of Jiangsu Pharmaceutical Co., Ltd., told cypress blue: at first, the reason for allowing local supplements was that the varieties of national essential drugs were insufficient and could not meet the local drug habits, so in 2000, a 15% agreement was formulated Only category B catalog was limited, and category A could not be supplemented locally After this agreement, the local government can make class B supplements according to its own clinical needs At present, the choice of class B supplement is generally clinical needs, but it does not conform to the principle of basic drugs According to statistics, there is a great interest problem in supplementary varieties The 2019 national catalog directly cancels local power, which is also a one size fits all interest He said that the main way to allow local supplements is to meet local drug habits, because some drugs can not be designated as a national unified use template But when it is impossible to supplement, a batch of local drugs will either change their medication habits in the direction of national health insurance or take the route of paying for their own expenses "The state is also encouraging the development of features, but only if it is in line with the basic principles of the drug catalog and allows health insurance funds to be spent on the cutting edge." To some extent, at the local level, the provincial government's support for the development of local pharmaceutical enterprises through the policy of medical insurance catalogue is limited Class B drugs added according to the regulations in the original provincial drug catalogue shall be gradually digested within 3 years For pharmaceutical companies, if they do not enter the national health insurance during the three-year transition period, they can only go through the way of self funded drugs or retail, which directly affects the sales team behind them According to statistics, retail drugstores account for about 20% of all drug sales If you follow the path of retail drugstores, it means that 80% of the market share will be given up If you give up the hospital market, without hospital endorsement, it is difficult to do later sales - prescription drugs must have the endorsement of medical institutions in order to have a future Before that, some experts in the industry said to saberland that if the product enters the medical insurance through medical insurance negotiation, it will have an impact on the future sales team of the product: the decrease is expected, in order to maximize the sales growth of drugs, the enterprise will expand the sales team accordingly; if the decrease exceeds the expected period, the enterprise may reduce the cost of marketing, adjust the sales team, and cut off some promoters Member If the product is not included in the medical insurance, the linkage effect is also very large Yesterday, it was revealed that a multinational pharmaceutical company was preparing to disband its sales team for its new hepatitis C product, which was launched this year, due to its failure to enter the national health insurance negotiation catalogue in 2019 Joe, a senior medical representative, explained to cypress blue that it's not important that it didn't get into the medical insurance, but the key is that the competitive products got into it Hepatitis C patients are cured one less, the overall number of patients has been declining, and the need to maintain the team is not great He further said: now many products, if everyone does not enter the medical insurance, there is still the possibility of development in the future If you don't get in and the competing products get in, everyone's curative effect is almost the same, but the price is much lower, and the patients are very sensitive to the price, it is obvious that the promotion work in the future will be difficult to carry out.